GeneOne Life Science Inc (011000) - Total Liabilities
Based on the latest financial reports, GeneOne Life Science Inc (011000) has total liabilities worth ₩78.31 Billion KRW (≈ $53.07 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GeneOne Life Science Inc net asset momentum to track the company's year-over-year net asset growth rate.
GeneOne Life Science Inc - Total Liabilities Trend (2009–2025)
This chart illustrates how GeneOne Life Science Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does GeneOne Life Science Inc generate to measure how efficiently the company converts operating cash flow to free cash.
GeneOne Life Science Inc Competitors by Total Liabilities
The table below lists competitors of GeneOne Life Science Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Perfect Corp.
NYSE:PERF
|
USA | $39.31 Million |
|
Venu Holding Corporation
NYSE MKT:VENU
|
USA | $171.70 Million |
|
Humasis Co. Ltd
KQ:205470
|
Korea | ₩90.75 Billion |
|
Chesapeake Gold Corp.
V:CKG
|
Canada | CA$13.06 Million |
|
Jinzhou Port Co Ltd A
SHG:600190
|
China | CN¥9.91 Billion |
|
Srivichaivejvivat Public Company Limited
BK:VIH
|
Thailand | ฿604.07 Million |
|
Dollar Industries Limited
NSE:DOLLAR
|
India | Rs5.90 Billion |
|
AVerMedia Technologies Inc
TW:2417
|
Taiwan | NT$1.82 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down GeneOne Life Science Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of GeneOne Life Science Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneOne Life Science Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneOne Life Science Inc (2009–2025)
The table below shows the annual total liabilities of GeneOne Life Science Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩78.31 Billion ≈ $53.07 Million |
+19.14% |
| 2024-12-31 | ₩65.73 Billion ≈ $44.54 Million |
+66.33% |
| 2023-12-31 | ₩39.52 Billion ≈ $26.78 Million |
-4.53% |
| 2022-12-31 | ₩41.40 Billion ≈ $28.05 Million |
-6.01% |
| 2021-12-31 | ₩44.04 Billion ≈ $29.85 Million |
+15.71% |
| 2020-12-31 | ₩38.06 Billion ≈ $25.79 Million |
+40.49% |
| 2019-12-31 | ₩27.09 Billion ≈ $18.36 Million |
+36.24% |
| 2018-12-31 | ₩19.89 Billion ≈ $13.48 Million |
+118.67% |
| 2017-12-31 | ₩9.09 Billion ≈ $6.16 Million |
-69.49% |
| 2016-12-31 | ₩29.81 Billion ≈ $20.20 Million |
+261.22% |
| 2015-12-31 | ₩8.25 Billion ≈ $5.59 Million |
+36.74% |
| 2014-12-31 | ₩6.03 Billion ≈ $4.09 Million |
-25.58% |
| 2013-12-31 | ₩8.11 Billion ≈ $5.50 Million |
-38.66% |
| 2012-12-31 | ₩13.22 Billion ≈ $8.96 Million |
+98.26% |
| 2011-12-31 | ₩6.67 Billion ≈ $4.52 Million |
-16.81% |
| 2010-12-31 | ₩8.02 Billion ≈ $5.43 Million |
-58.48% |
| 2009-12-31 | ₩19.30 Billion ≈ $13.08 Million |
-- |
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more